The deal brings Exact Sciences' flagship screening test for colorectal cancer, Cologuard, under Abbott's umbrella.
Abbott said it has received all regulatory clearances necessary to buy the cancer screening firm.
Abbott (NYSE: ABT) announced today that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026.
Abbott (NYSE:ABT) announced today that it completed its acquisition of cancer diagnostics developer Exact Sciences.
Abbott Laboratories narrowed its full-year outlook as sales of COVID-19 tests slide. COVID-19 test sales in the second quarter dropped 46% from the year before. Second-quarter earnings and revenue ...
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care ...
WHO Prequalification approval allows Abbott ( <a href="http://www.Abbott.com" id="59c52bdb-d8e4-395f-aca5-b1ec1e14bb1c"> www.Abbott.com </a> ) to bring critical ...
Abbott, a healthcare company focused on the development, manufacturing and marketing of pharmaceuticals and medical products, will collaborate with Genetics Laboratory on developing a diagnostic test ...
On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying ...
WASHINGTON (AP) — The Food and Drug Administration said Wednesday that Abbott Laboratories is recalling up to 359 million testing strips used by diabetics because they can give falsely low blood sugar ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results